Introduction
DLI has been used to treat molecular or overt relapse after allogeneic hematopoietic cell transplantation (allo-HCT), as well as to convert mixed chimerism into full donor chimerism through a GVL effect. However, DLI is also associated with the development or worsening of acute or chronic GVHD. DLI's efficacy is evident in allo-HCT for CML, which leads to a high incidence of durable cytogenetic and molecular remissions. 1 However, its efficacy in other hematologic diseases, such as acute leukemia, is much less convincingly documented. 2, 3 Thus, it would be of great interest to identify a surrogate marker of the efficacy of DLI prior to DLI administration in such malignancies.
The action of DLI is primarily based on the function of allo-reactive donor T-lymphocytes. 4 The capability of the T lymphocytes to become reactive depends largely on a stimulatory signal provided by the B7/CD28 ligand interaction, between the APCs and T-cells. 5 The Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), also expressed in T-cells, is a homologous molecule of CD28 and competes for binding with B7. 5 CTLA-4, however, provides a negative signal, thus downregulating T-cell activation. 6 The corresponding gene for CTLA-4 encompasses several single-nucleotide polymorphisms (SNPs). 7 Studies in humans have correlated certain of these polymorphisms with different autoimmune disorders through an impact on T-cell activation. 8 Among those SNPs already studied, CT60 SNP seems to occupy a key role, as it represents the only SNP analyzed repeatedly related to the T-cell activation status. 5, 8, 9 The aim of this study was to analyze CT60 SNP as a surrogate marker for the outcome of DLI after allo-HCT in acute leukemia.
Patients and methods
We conducted a retrospective study by genotyping the CT60 SNP of 79 allo-HCT/DLI donors. We documented the molecular-, chimerism-and hematological status (relapse, mixed or complete chimerism) and grade of GVHD of the corresponding patients at the first DLI and at the end of evaluation. Prior to allo-HCT all patients and donors had given their written informed consent for any research use of their biological material(s) over time. At the first DLI no patient received immunosuppression or chemotherapy, except four who received an azacytidinebased regimen. In cases of no response or relapse post-DLI, salvage chemotherapy was given.
CT60 was genotyped using PCR and subsequent Pyrosequencing technology (Biotage, Uppsala, Sweden 
Definitions
Hematological relapse was defined as blasts in the peripheral blood (PB) or more than 5% blasts in the BM. We identified mixed chimerism when signals from both donor and recipient were present using the FISH (recipient percentage 41%) or VNTR (variable number tandem repeat) technique (43%). The reappearance of a molecular marker was defined as molecular relapse. Preemptive DLI was given to patients with an increased risk for relapse (worse prognosis karyotype). Response to DLI was defined as the conversion to complete chimerism (CC), negative molecular marker or absence of blasts in PB/BM or remaining in CR in cases of preemptive DLIs. Time-toprogression (TTP) represented the time between the first DLI and the documentation of relapse. Acute GVHD (aGVHD) was determined as described. 10 The time end point of the study was either date of death or the date of evaluation (31 May 2010).
Statistical analyses
The primary end point of the analysis was the best response to DLI according to the CT60 SNP genotype and the secondary end points were DLI-induced aGvHD and the presence of a sustained CC.
To explore the role of the three different genotypes of the CT60 SNP (AA, AG and GG), we categorized the different genotypes into two groups: AA/AG vs GG (that is, presence vs absence of A allele) and AA vs AG/GG (that is, presence vs absence of G allele). If a statistical correlation turned out to be significant for both groups, then a difference would exist among all of the three genotypes (AA, AG and GG). If only one group was statistically important, then that difference would exist within that group (for example, only the presence vs absence of A allele would be important).
Fisher's exact test and the Kruskal-Wallis test were used for direct statistical correlations and regression model, respectively. The odds ratios (ORs) for showing post-DLI responses according to genotype were compared using a Cox PH model.
Results

Patient characteristics and outcome
All 79 acute leukemia patients (16 ALL, 63 AML, male 59%) received PBSCs as graft source from a sibling (n ¼ 26) or an unrelated donor (UD; n ¼ 53) and achieved CR at day þ 30, as evaluated by standard diagnostic procedures (Table 1) . Starting on median day þ 199 (range 39-3694) they received a median of 4 (1-20) DLIs with a median dose of 10.4 Â 10 6 CD3 þ cells per kg recipient body weight. A total of 27/79 (34%) patients showed an evident post-DLI response (as defined earlier). aGVHD developed in 32/79 patients (40%) and 42/79 (53%) showed allo-reactivity of any kind (development of aGVHD and/or GVL). In 37/79 (47%) patients there was evidence of neither GVL nor aGVHD.
Relapse after a DLI response occurred in 6/27 patients (relapse also being their DLI indication) after a median TTP of 205 days (range 30-1100); all died. Eight of the 52 non-responders achieved sustained CC with an azacytidine-(n ¼ 5) or aracytidine-based (n ¼ 3) salvage chemotherapy. Overall, 29/79 patients were in CC and alive at the date of evaluation (Table 1 ). All other patients had succumbed to their malignancy, in spite of salvage chemotherapy.
Donor CT60, clinical parameters and post-DLI response
The CT60 genotyping of the 79 donors showed 17 with AA, 26 with AG and 36 with GG genotype. We univariately analyzed the above CT60 distribution in regard to (I) best DLI response; (II) GvHD development; (III) both; (IV) neither, and found no statistically significant correlation (Table 2) . Further, in a multivariable regression model we analyzed donor CT60 with several clinical parameters (donor sex, relation, reason for DLI, total cells infused and development of post-DLI aGvHD) for correlation with DLI response. We found a positive correlation for response in patients who received DLIs for non-hematological relapse (P ¼ 0.008), as well as in cases with concomitant aGvHD development (P ¼ 0.02). The other parameters did not correlate with the outcome.
Regardless of the reason for DLI, 6/27 of the DLI responders did not remain in CC. Thus, we analyzed the CT60 distribution and the OR for achieving sustained CC in this group and found no statistical difference in CT60 distribution compared with those achieving sustained CC (P ¼ 0.22). However, the OR for remaining in CC was greater in the presence of the 'A' allele, but without reaching statistical significance ('A' allele, OR Table 3 ). The analysis of all 79 patients (Table 3 ) also approached or achieved statistical significance for the presence of the 'A' allele (CT60 distribution P ¼ 0.06, 'A' allele, OR 2.61, 95% CI 0.99-6.83 vs 'G' allele, OR ¼ 0.42, 95% CI 0.14-1.26, P OR ¼ 0.05, Table 3 ). The fact that only the 'A' allele was statistically significant demonstrates the significance of this allele in its homologous or heterozygous form.
Four of the 37 patients with no allo-reactivity survived in CC due to salvage chemotherapy. Despite the very low numbers, the presence of the 'A' allele again indicated a better prognosis ('A' allele, OR ¼ 1.39, 95% CI 0.32-6.07 vs 'G' allele, OR ¼ 0.53, 95% CI 0.1-2.8 for a sustained CR, P OR ¼ 0.45). No difference was observed in the median cumulative dose of CD3 þ cells infused in patients achieving sustained CC (11.5 Â 10 6 /kg) and those who died (10 Â 10 6 /kg). In the 42 patients with evident allo-reactivity, cell doses were 11.6 and 11.2 Â 10 6 /kg for patients alive and dead, respectively. No difference was observed in any other subgroup. Again, outcomes in the presence of the 'A' allele were better. In the UD group (n ¼ 53) (see also Table 1 ) the OR was 2.52 ('A' allele) and 0.27 ('G' allele) (95% CI 0.79-7.96 and 0.05-1.29, P-values 0.11 and 0.1, respectively). Twentysix of the UD recipients showed evident allo-reactivity. Here, OR was 3.3 and 0.1 for 'A' and 'G' alleles. Similar values were observed in the 21 patients with aGVHD (data not shown). In the 13 DLI responders the ORs were 6.67 and 0.24, respectively. Results in the 27 patients with no allo-reactivity, as well as in the 26 'sibling' cases, were similar (data not shown). However, CT60 distribution and the P OR approached but failed to reach statistical significance in all patients (UD and siblings), while the 95% confidence intervals showed a large range.
Analysis of the 45 patients who received DLIs due to hematological relapse also revealed a similar importance of the 'A' allele. Thus, ORs for survival were 1.73 and 1.08 for the 'A' and 'G' allele (P OR insignificant), whereas the values were 5.2 and 0.19, respectively, in the 21 patients with DLI reactivity (again, P OR was insignificant). The numbers changed in the 19 patients with aGVHD, showing an OR of 15 ('A' allele, P OR ¼ 0.09, 95% CI 0.6-374.82) and 0.14 ('G' allele, P OR ¼ 0.36, 95% CI 0.002-18.95). Both of the 9 DLI responders as well as the 24 patients with no allo-reactivity followed the same trend in the presence of the 'A' allele (data not shown). Again, the CT60 distribution and the P OR did not achieve statistical significance. Finally, we searched for differences in the TTP of the six responders who died. One patient had received DLIs from an 'AA' donor (TTP 1100 days), two had received 'AG' DLIs (median TTP 50 days) and three had received 'GG' (median TTP 620 days). No difference in the median TTP was observed in an 'AA/AG' vs 'GG' analysis (590 vs 620 days).
Discussion
First, our results provide support for the role of CT60 as a surrogate marker for the outcome of DLIs in relapse after allo-HCT for acute leukemia. Second, they help understand the role of CTLA-4 in regulating lymphocyte activity, as DLI outcomes primarily depict this activity.
A quick 'scan' of the CT60 SNP distribution (either unior multivariately) showed no immediate correlation with the emergence of aGVHD or hematological response post-DLI. This analysis, although simple in its concept, is not devoid of severe limitations, as it does not take into consideration the final status of the patient (alive/in CC vs relapse/death). Thus, when we evaluated only the patients who clearly developed a post-DLI GVL response, we observed an improved chance among them for sustaining CC in the presence of the 'A' allele compared with the 'G' allele. Analysis of all patients using a 'dead/alive' methodology again identified an excessive influence of the 'A' allele for a better outcome. In fact, every subgrouping according to development of post-DLI allo-reactivity together with the patient's final status resulted in the same 'A' allele dynamic, which points to a linkage of this allele with a better chance of surviving post-DLI.
Only a subset of our statistical analyses reached true significance; however, all showed large confidence intervals. This could point towards a significant outcome in all subgroupings, when analysis of a larger population becomes feasible. However, the fact that all of our findings pointed in the same direction enables us to hypothesize an independent role of the 'A' allele. Schmid et al. 3 have concluded that DLIs do have a role in the treatment of leukemia relapse after allo-HCT. However, only a subset of patients can benefit from this approach. Our study supplements their efforts, providing a surrogate marker for predicting the outcome of DLIs in this setting.
Regarding the role of the CT60 SNP in influencing lymphocyte activity, we believe there are hints originating in our analysis of cell dose infused. In the 42 cases with evidence of allo-reactivity, where the 'A' allele revealed a true statistical significance, one could hypothesize that the patients who eventually relapsed received different DLI doses than the ones who remained in CC. Our results did not support this hypothesis. It has been proposed that the CTLA-4 acts through one of five possible mechanisms and that its SNPs may, in turn, affect these mechanisms; 5,7 the net result is a linkage of the presence of specific SNPs with T-cell activation status. 8 We did not measure this status, but the fact that with the same cumulative CD3 þ dose those patients who received DLIs from an 'A' donor had an increased OR for a sustained CC may be interpreted as the 'A'-infused cells being more 'competent' in initiating an ongoing GvL effect than were their 'G' counterparts.
Two recent reports showed conflicting results regarding the role of CT60 in the outcome of allo-HCT for acute leukemia. 7, 11 Our study is the first that confines the possible influence of different clinical parameters, as it uses an in vivo model where many of these parameters were the same for all of the patients (that is, all leukemia patients, identical stem-cell source (PBSCs), treatment in a single center and receiving the same treatment for relapse (DLIs), which was highly dependent on T-cell activation status). Thus, our study clearly adds to the elucidation of the role of the CT60 SNP, at least in leukemia allo-HCT patients.
Patients who initially responded post-DLI but finally died did not differ in their TTP according to 'AA/AG' or 'GG' DLIs. This finding is very difficult to interpret as it stems from a very small number of cases. Additionally, half of these patients had received concurrent chemotherapy with DLIs, which makes an explanation even more difficult. Larger patient recruitment is necessary to allow conclusions to be drawn.
It is also interesting that no allo-reactivity DLI patients showed a trend towards a better outcome in the presence of the 'A' allele. It is unknown whether this will be confirmed through the analysis of a larger population, but it may be attributable to a subclinical GVL effect. In any case, this finding could stimulate the debate about underlying mechanisms. As proposed, CT60 SNP alters CTLA-4 expression. 7, 8 However, other investigators theorize that the in vivo effect of CTLA-4 may be mediated by cells other than T-cells, or that CTLA-4 protein expression during Tcell activation could, in fact, inhibit CTLA-4 ligation with B7. 12 In the present study, we did not investigate the mechanisms through which CT60 correlates with lymphocyte activity and the observed chance for survival. In order to understand exactly the role of the CT60 SNP, CT60 genotyping should be combined with in vivo measurement of T-cell activation status and CTLA-4 protein levels in every subcategory of a DLI population, continuously during the course of treatment. This could elucidate whether the mechanism responsible lies in altering CTLA-4 expression, when such an alteration becomes clinically important and under what circumstances, or whether this process is only an 'innocent by-stander phenomenon'. Our group is currently working on this project.
In conclusion, our study provides hints of an independent linkage of the CT60 'A' allele with an improved chance of sustained CR post-DLI, making its genotyping prior to DLI administration a meaningful diagnostic test. How this linkage emerges remains to be elucidated.
